<DOC>
	<DOCNO>NCT00190463</DOCNO>
	<brief_summary>Empirical antifungal treatment gold standard patient neutropenic persistent fever broad-spectrum antibiotic . The rational fungal infection difficult early diagnose , life-threatening . Historical trial show small benefit survival strategy use . According drug usde strategy , safety cost may concern . However , since routine practice implement hematology , new non-invasive biological diagnostic method available early diagnose fungal infection , galactomannan antigenemia aspergillosis . The goal study show limit administration antifungal set patient clinical foci infection , patient positive galactomannan antigenemia reduces risk toxicity antifungal drug , impact overall mortality patient treat chemotherapy hematologic malignancy .</brief_summary>
	<brief_title>Comparison 2 Antifungal Treatment ( Empirical Versus Pre-Empirical ) Strategies Prolonged Neutropenia</brief_title>
	<detailed_description>Patients eligible hematologic malignancy , receive chemotherapy expect neutropenic phase &gt; 10 day . Patients randomize accord 1:1 ratio receive either usual empirical strategy ( antifungal introduce persistent fever 4 day broad-spectrum antibacterial ) pre-empirical strategy ( administration antifungal limit patient pneumonia , septic shock , sinusitis , grade 3 mucositis , aspergillus colonization , liver splenic abscess , positive galactomannan antigenemia ) . The antifungal administer deoxycholate amphotericin B liposome amphotericin B , accord creatinin clearance . This strategy apply first 14 day persistent fever , therapy leave discretion investigator . The primary endpoint survival neutrophil recovery , , case persistent neutropenia , day 60 late . Secondary objective incidence invasive fungal infection ( IFI ) , IFI-free survival , number febrile day , renal function study completion .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Malignant Hemopathy Induction consolidation phase chemotherapy , expect neutropenia ( &lt; 500/mm3 ) least 10 day Hospitalisation aplasia allogeneic haematopoietic stem cell transplant Previous fungal infection accord EORTCMSG criterion Active fungal infection accord EORTCMSG criterion Previous anaphylactic intolerance polyenes know aspergillosis infection Sepsis Pneumopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>aspergillosis</keyword>
	<keyword>antifungal therapy</keyword>
	<keyword>empirical antifungal treatment</keyword>
</DOC>